scholarly journals Is There Any Relationship between Plasma 25-Hydroxyvitamin D3, Adipokine Profiles and Excessive Body Weight in Type 2 Diabetic Patients?

2017 ◽  
Vol 15 (1) ◽  
pp. 19 ◽  
Author(s):  
Joanna Kocot ◽  
Piotr Dziemidok ◽  
Małgorzata Kiełczykowska ◽  
Jacek Kurzepa ◽  
Grzegorz Szcześniak ◽  
...  
Keyword(s):  
Body Weight ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Excessive Body Weight ◽  
Type 2 Diabetic

Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study

2008 ◽  
Vol 24 (8) ◽  
pp. 624-628 ◽  
Author(s):  
Giacomo Zoppini ◽  
Giuseppe Verlato ◽  
Giovanni Targher ◽  
Enzo Bonora ◽  
Maddalena Trombetta ◽  
...  
Keyword(s):  
Body Weight ◽  
Pulse Pressure ◽  
Total Mortality ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Daily consumption of fruit-flavored yoghurt enriched with vitamins B contributes to lower energy intake and body weight reduction, in type 2 diabetic patients: a randomized clinical trial

2019 ◽  
Vol 10 (11) ◽  
pp. 7435-7443 ◽  
Author(s):  
Amalia E. Yanni ◽  
Alexander Kokkinos ◽  
Georgia Psychogiou ◽  
Panagiota Binou ◽  
Kleio Kartsioti ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Reduction ◽  
Lower Energy ◽  
Diabetic Patients ◽  
Vitamin B ◽  
Daily Consumption ◽  
Type 2 Diabetic Patients ◽  
Body Weight Reduction ◽  
Type 2 Diabetic

Fruit-yoghurt enriched with vitamins B promotes body weight reduction and improves vitamin B status and homocysteine levels in T2DM patients.

scholarly journals Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes: a retrospective study

2020 ◽  
Author(s):  
Mitsunobu Kubota ◽  
Eri Shiroyama ◽  
Kanako Tanaka ◽  
Yoko Yoshii
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Diabetic Patients ◽  
Protective Effects ◽  
Renal Protection ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Before And After ◽  
Type 2 Diabetic

Abstract Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic patients with chronic kidney disease in a large clinical study. These results suggest that SGLT-2 inhibitors could be used not only for hypoglycemic effects, but also for renal protective effects in patients with type 2 diabetes. It is not fully understood in which contexts the use of SGLT-2 inhibitors is likely to exert its renal protective effects. The purpose of this study was to clarify the profiles of patients in whom SGLT-2 inhibitors are more likely to exert a renal protective effect in clinical practice. We examined renal function and urinary albumin changes in short-term use of SGLT-2 inhibitors by patient background. Methods We retrospectively analyzed the medical record information of sixty-three type 2 diabetic patients (33 males, 30 females, average age 53.0 ± 13.0 years) who were given usual doses of a SGLT-2 inhibitor. We investigated changes in body weight, blood pressure, glucose metabolism index, lipid metabolism index, estimated glomerular filtration rate (eGFR) and albuminuria (urinary albumin-to-creatinine ratio, UACR) three months before and after administration of a SGLT-2 inhibitor. Results Three months after administration of an SGLT-2 inhibitor, there were improvements in glucose tolerance, weight loss, blood pressure, and lipid indices. In all cases, there was no significant change in eGFR, but UACR decreased significantly. UACR decreased regardless of Angiotensin II Receptor Blocker medication and significantly decreased in nephropathy patients with microalbuminuria or overt albuminuria. UACR decreased only in the group in which blood pressure, body weight, and hemoglobin A1c decreased before and after administration of the SGLT-2 inhibitor. Conclusions Our study shows that the renoprotective effects of SGLT-2 inhibitors are more likely to be exerted in diabetic nephropathy patients who have advanced to at least microalbuminuria stage, and in addition to direct renal protection, the comprehensive effects of SGLT-2 inhibitors, which lower body weight, blood pressure, and blood glucose, are also important for their renal protection effects.

scholarly journals Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in type 2 diabetes

2020 ◽  
Author(s):  
Mitsunobu Kubota ◽  
Eri SHiroyama ◽  
Kanako Tanaka ◽  
Yoko Yoshii
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Diabetic Patients ◽  
Protective Effects ◽  
Renal Protection ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Before And After ◽  
Type 2 Diabetic

Abstract Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic patients with chronic kidney disease in a large clinical study. These results suggest that SGLT-2 inhibitors could be used not only for hypoglycemic effects, but also for renal protective effects in patients with type 2 diabetes. It is not fully understood in which contexts the use of SGLT-2 inhibitors is likely to exert its renal protective effects. The purpose of this study was to clarify the profiles of patients in whom SGLT-2 inhibitors are more likely to exert a renal protective effect in clinical practice. We examined renal function and urinary albumin changes in short-term use of SGLT-2 inhibitors by patient background. Methods We retrospectively analyzed the chart information of sixty-three type 2 diabetic patients (33 males, 30 females, average age 53.0 ± 13.0 years) who were given usual doses of a SGLT-2 inhibitor. We investigated changes in body weight, blood pressure, glucose metabolism index, lipid metabolism index, estimated glomerular filtration rate (eGFR) and albuminuria (urinary albumin-to-creatinine ratio, UACR) three months before and after administration of a SGLT-2 inhibitor. Results Three months after administration of an SGLT-2 inhibitor, there were improvements in glucose tolerance, weight loss, blood pressure, and lipid indices. In all cases, there was no significant change in eGFR, but UACR decreased significantly. UACR decreased regardless of Angiotensin II Receptor Blocker medication and significantly decreased in the nephropathy stage 2 and 3 groups. UACR decreased only in the group in which blood pressure, body weight, and HbA1c decreased before and after administration of the SGLT-2 inhibitor. Conclusions Our study shows that SGLT-2 inhibitors are independent of renin-angiotensin system (RAS) inhibitors, and in addition to direct renal protection, the comprehensive effects of SGLT-2 inhibitors, which lower body weight, blood pressure, and blood glucose, are also important for their renal protection effects.

scholarly journals Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients

2010 ◽  
Vol 13 (3) ◽  
pp. 378 ◽  
Author(s):  
Giuseppe Derosa ◽  
Pamela Maffioli ◽  
Ilaria Ferrari ◽  
Ilaria Palumbo ◽  
Sabrina Randazzo ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Body Weight ◽  
Density Lipoprotein ◽  
Control Group ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Hs Crp ◽  
One Year ◽  
Type 2 Diabetic

Purpose. Comparison of the effects of one year treatment with sibutramine compared to placebo on body weight, glycemic control, lipid profile, and insulin resistance parameters in type 2 diabetic patients. Methods. Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP). Results. We observed a faster improvement of HbA1c, FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group. A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups. Conclusions. Sibutramine gave a faster improvement of glycemic control, and of insulin resistance parameters compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.

scholarly journals Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients

2015 ◽  
Vol 36 (2) ◽  
pp. 200-208 ◽  
Author(s):  
Ping Feng ◽  
De-min Yu ◽  
Li-ming Chen ◽  
Bao-cheng Chang ◽  
Qiu-di Ji ◽  
...  
Keyword(s):  
Body Weight ◽  
Waist Circumference ◽  
The Body ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals The energy intake modulates the association of the –55CT polymorphism of UCP3 with body weight in type 2 diabetic patients

2013 ◽  
Vol 38 (6) ◽  
pp. 873-877 ◽  
Author(s):  
E Lapice ◽  
A Monticelli ◽  
S Cocozza ◽  
M Pinelli ◽  
A Giacco ◽  
...  
Keyword(s):  
Body Weight ◽  
Energy Intake ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis

2020 ◽  
Vol 19 (10) ◽  
pp. 2213-2217
Author(s):  
Kaiping Lin ◽  
Qi Lv ◽  
Xiaoling Yang ◽  
Ting Lin ◽  
Min Feng ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Basal Insulin ◽  
Receptor Agonist ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic

Purpose: To compare the effectiveness of glucagon-like peptide 1 receptor agonist with that of basal insulin in type 2 diabetes patients. Methods: Type-2 diabetes patients who were insensitive to metformin were treated with glucagon-like peptide 1 receptor agonist (GP cohort, n = 115) or basal insulin (BI cohort, n = 152) with metformin. Hemoglobin A1c (HbA1c) level and body weight were determined, and adverse effects also recorded. Results: After 16 weeks of treatment, glucagon-like peptide 1 receptor agonist did not significantly reduce HbA1c levels (7.45 ± 2.11 % vs. 7.01 ± 2.01, p = 0.107). In contrast, basal insulin significantly reduced the levels of HbA1c (7.91 ± 2.98 % vs. 7.13 ± 2.22 %, p = 0.010, q = 3.852). Glucagon-likepeptide 1 receptor agonist reduced the body weight of patients (65.25 ± 7.55 kg vs. 62.16 ± 6.15 kg, p = 0.0008, q = 5.121), unlike basal insulin (63.71 ± 6.15 vs. 62.65 ± 6.76 kg, p = 0.154). Conclusion: Glucagon-like peptide 1 receptor agonist and basal insulin + metformin produce identical effectiveness in the treatment of type-2 diabetic patients. Keywords: Glucagon-like peptide-1 receptor agonist, Glycemic control, Insulin, Metformin, Type-2 diabetes

Sign in / Sign up

Export Citation Format

Share Document